Mood Disorders

Economic Burden and Healthcare Resource Utilization Among Individuals with Major Depressive Disorder Utilizing Anti-Anxiety Medications in the United States

Abstract: Background: Anxiety is a prevalent symptom among patients with major depressive disorder (MDD). MDD patients with anxiety symptoms frequently experience more severe depression, ...

Erin Ferries ;

01/19/2023

Effects of Adjunctive Brexpiprazole on Patient Life Engagement in Major Depressive Disorder: A Phase 4, Open-Label, Interventional Study

Abstract: Background: Patient life engagement is a broad term describing positive health aspects across four domains (emotional, physical, social, cognitive). The 10-item Inventory of Dep...

Erin MacKenzie , PhD;

Liz Kelly ;

01/19/2023

COMP360 Psilocybin Therapy in Treatment-Resistant Depression: Results of a Large Randomized Controlled Phase IIb Monotherapy Study and an Exploratory Uncontrolled Adjunctive Therapy Study

Abstract: COMP360 is a synthetic purified form of psilocybin in development for treatment of adults with treatment-resistant depression (TRD). COMP360 psilocybin therapy combines oral COM...

Matt Young ;

01/19/2023

A New Methodological Approach to Improve the "Real Word" Effectiveness of Ketamine Infusion Therapy for Treatment-Resistant Depression

Abstract: Objective: Ketamine is recognized as a rapidly acting antidepressant; however, discrepancies exist between the "Efficacy" reported in research studies (70-85%) versus significan...

Gerald Grass ;

01/19/2023

Impact of AXS-05 (Dextromethorphan-Bupropion), an Oral NMDA Receptor Antagonist, on Anhedonic Symptoms in Major Depressive Disorder

Abstract: Background: Treatments for MDD that can improve both overall depressive and anhedonic symptoms are urgently needed. AXS-05 (dextromethorphan-bupropion) is a novel, oral, inv...

Zachariah Thomas , DPM, AACFAS;

01/19/2023

Efficacy of Adjunctive Cariprazine on Anxiety Symptoms in Patients With Major Depressive Disorder and Baseline Anxiety: Post Hoc Analysis of a Randomized Controlled Trial

Abstract: Background: Adjunctive cariprazine was evaluated in patients with major depressive disorder (MDD) and inadequate response to monotherapy antidepressant treatment (ADT), stratifi...

Vladimir Maletic , MD;

Leslie Citrome , MD;

01/19/2023

Healthcare Resource Utilization 6 Weeks Post-Diagnosis Among Individuals With Major Depressive Disorder in the United States

Abstract: Background: Although major depressive disorder (MDD) is associated with high economic burden, short-term healthcare resource utilization (HCRU) is poorly understood in patients ...

Ellison Suthoff , MBA, BS ;

01/19/2023

A Real-World Observational Study Design Comparing Vortioxetine With Standard of Care Monotherapy Treatments: Assessment of Patient Global Improvement, Goal Attainment, and Patient-Centric Measures in Major Depressive Disorder

Abstract: Aim: To gain insights on the real-world treatment experiences of patients with major depressive disorder (MDD) through PatientsLikeMe (PLM), an online community platform. The pr...

Christopher Blair , MS;

01/19/2023

Efficacy of Fremanezumab Quarterly and Monthly Dosing Regimens in Patients With Migraine and Psychiatric Comorbidities

Abstract: Introduction: Migraine with psychiatric comorbidities has been associated with increased disability, pain, and reduced quality-of-life.

Maggie Kane ;

Richard Lipton , MD;

01/19/2023

Fremanezumab for Preventive Migraine Treatment in Patients With Major Depressive Disorder: Baseline Patient Characteristics in the Phase 4 UNITE Study

Abstract: Introduction: Major depressive disorder (MDD) is a common migraine comorbidity. Fremanezumab, a humanized monoclonal antibody selectively targeting calcitonin gene-related pepti...

Maggie Kane ;

Richard Lipton , MD;

01/19/2023